Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 13/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 15/20 | 0.63 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.63 |
| ▸ | HDAC10 | Q969S8 | 9/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 9/20 | 0.63 |
| ▸ | HDAC7 | Q8WUI4 | 9/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 0.63 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | BRD4 | O60885 | 1/20 | 0.62 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | LTA4H | P09960 | 1/20 | 0.62 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15480439 | 0.94 | MEN1 (0.68) | HDAC3HDAC8NCOR2HDAC1MEN1 | |
| SCHEMBL18660186 | 0.94 | MEN1 (0.68) | HDAC3HDAC8NCOR2HDAC1MEN1 | |
| SCHEMBL7700654 | 0.92 | MEN1 (0.69) | HDAC1MEN1ALDH1A1CYP2C9HPGD | |
| SCHEMBL15480467 | 0.88 | MEN1 (0.78) | HDAC3HDAC8NCOR2MEN1ALDH1A1 | |
| SCHEMBL7774833 | 0.87 | MEN1 (0.67) | MEN1ALDH1A1CYP2C9HPGDCYP2C19 | |
| SCHEMBL7774657 | 0.87 | MEN1 (0.67) | MEN1ALDH1A1CYP2C9HPGDCYP2C19 | |
| SCHEMBL7776199 | 0.87 | MEN1 (0.67) | MEN1ALDH1A1CYP2C9HPGDCYP2C19 | |
| SCHEMBL8133836 | 0.87 | MEN1 (0.60) | HDAC3HDAC8NCOR2HDAC1HDAC2 | |
| SCHEMBL13298956 | 0.87 | MEN1 (0.67) | MEN1ALDH1A1CYP2C9HPGDCYP2C19 | |
| SCHEMBL31635263 | 0.85 | HDAC1 (0.83) | HDAC3HDAC8NCOR2HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB (SE) | 2021-03-04 | — | — | US | disclosed |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENT AB (SE) | 2017-01-26 | — | — | US | disclosed |
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | CERENO SCIENTIFIC AB | 2014-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051716-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC8 4/4885NCOR2 315/4885 |
| US-20170020874-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC8 4/4885NCOR2 315/4885 |
| US-20210060014-A1 | COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC2 | HDAC3 1/4885HDAC8 4/4885NCOR2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.